Department of Neurology, UniversitätsMedizin Mannheim, University of Heidelberg, Mannheim, Germany.
Cerebrovasc Dis. 2011;32(4):349-53. doi: 10.1159/000330346. Epub 2011 Sep 15.
Patients with posterior circulation stroke (PCS) were underrepresented in or even excluded from the large clinical trials investigating acute therapy with thrombolysis. Therefore, the knowledge about potential benefits and risks of thrombolysis in PCS is sparse.
From July 2004 until June 2007, 237 stroke patients were treated with thrombolysis within 3 h after onset of symptoms in our stroke unit. Baseline characteristics, etiology, CT/MRI stroke patterns, clinical outcome, and complications of patients with PCS were compared to those with anterior circulation stroke (ACS).
There were 30 patients in the PCS group; 198 had ACS. In the PCS group, less patients had a history of prior stroke (0/30 vs. 31/198 (15.7%), p = 0.02) and less were treated with platelet inhibitors (6/30 (20.0%) vs. 83/198 (41.9%), p = 0.02). Onset to treatment time was higher in the PCS group (156.2 ± 23.2 vs. 141.1 ± 30.7, p = 0.01). Small vessel disease occurred more often in PCS patients (10/30 (33.3%) vs. 12/198 (6.1%), p < 0.001), whereas stroke of undetermined cause was less frequent (5/30 (16.7%) vs. 75/198 (37.9%), p = 0.02). Correspondingly, PCS patients had more lacunar (13/30 (43.3%) vs. 15/198 (7.3%), p < 0.001) strokes on CT/MRI. Patients with PCS had significantly lower median NIHSS scores after 2 and 24 h, whereas the median NIHSS and mRS scores at discharge as well as the mRS score at the 3-month follow-up, although still lower, did not differ significantly between both groups. Outcome was similar with regard to complications and mortality.
Patients with PCS have a higher rate of small vessel disease and lacunar stroke. In terms of potential benefits and risks of thrombolysis, we could demonstrate no significant differences between PCS and ACS. Acute PCS patients should be diagnosed and treated with the same elaborateness as ACS patients.
在后循环卒中(PCS)患者中,大型溶栓治疗临床试验的代表性不足,甚至将其排除在外。因此,关于 PCS 患者溶栓治疗的潜在获益和风险的知识非常有限。
2004 年 7 月至 2007 年 6 月,在我们的卒中单元中,对 237 例症状发作后 3 小时内接受溶栓治疗的卒中患者进行了研究。将 PCS 患者与前循环卒中(ACS)患者的基线特征、病因、CT/MRI 卒中类型、临床结局和并发症进行了比较。
PCS 组有 30 例患者,ACS 组有 198 例患者。在 PCS 组中,既往卒中史的患者较少(0/30 例 vs. 31/198 例(15.7%),p=0.02),接受血小板抑制剂治疗的患者较少(6/30 例 vs. 83/198 例(41.9%),p=0.02)。PCS 组的起病至治疗时间较高(156.2±23.2 分钟 vs. 141.1±30.7 分钟,p=0.01)。小血管疾病在 PCS 患者中更常见(10/30 例 vs. 12/198 例(6.1%),p<0.001),而不明原因的卒中较少见(5/30 例 vs. 75/198 例(37.9%),p=0.02)。相应地,PCS 患者 CT/MRI 上的腔隙性卒中更多(13/30 例 vs. 15/198 例(7.3%),p<0.001)。在 2 小时和 24 小时后,PCS 患者的 NIHSS 中位数评分显著降低,而 NIHSS 和 mRS 评分出院时以及 3 个月随访时的评分虽然仍较低,但两组间无显著差异。并发症和死亡率方面的结局也相似。
PCS 患者小血管疾病和腔隙性卒中的发生率较高。在溶栓治疗的潜在获益和风险方面,我们没有发现 PCS 和 ACS 之间有显著差异。急性 PCS 患者应与 ACS 患者一样接受详细的诊断和治疗。